KOSPIBiotech & Pharma102460

Reyon Pharmaceutical

₩9,300▼ 1.06%2026-11-18 close
Market Cap
₩172.9B
Turnover
₩56,974,210
Volume
6.1K
Shares out.
18.6M
PER
—
PBR
1.0×
EPS
-₩2,316
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Chungju plant ramp-up and NG101 data test the earnings turnaround

Reyon Pharmaceutical swung to an operating loss of KRW 30.3 billion in 2025 and has booked operating losses in every quarter since Q3 2025, so Chungju plant utilization and follow-up NG101 data are the variables most closely watched for the earnings direction.

  1. 1

    Disclosed revenue fell for three straight years from 2023 through 2025, and Q3 2026 revenue of KRW 34 billion was down 9.4% year on year.

  2. 2

    Depreciation from the Chungju plant pushed up cost of sales, taking the 2025 operating margin to -20.7%, and the Q3 2026 operating loss widened to KRW 9.25 billion from the prior quarter.

  3. 3

    Debt-to-equity stood at 111.1% at end-2025 (total liabilities KRW 244.8 billion against total equity KRW 220.3 billion), and the company is widening funding through a KRW 21 billion CB issue and a plan to monetize part of the Chungju site for KRW 100 billion or more.

  4. 4

    The company reported that the NG101 low-dose group averaged 1.1 injections over 52 weeks versus 9.8 annual injections on standard therapy, about 89% fewer, although the trial is still in Phase 1/2a.

  5. 5

    According to a company announcement dated May 27, 2026, the chemical segment stayed profitable in Q1 2026 with KRW 26.4 billion in revenue and KRW 2.7 billion in operating profit; this is a company-announced figure, separate from the disclosed results.

02

Business structure

Reyon Pharmaceutical runs two arms: chemical pharmaceuticals and a bio production base.

The company said chemical-segment operating profit rose from KRW 4.6 billion in 2023 to KRW 5.6 billion in 2024 and KRW 8.3 billion in 2025, and in a May 27, 2026 announcement it said the segment stayed profitable in Q1 2026 with KRW 26.4 billion in revenue and KRW 2.7 billion in operating profit.

Product sales rose as a share of total revenue, from 68.6% in 2021 to 76.5% in Q3 2025. On an annual basis for 2025, merchandise sales fell 5.5% and other sales such as toll processing fell 17.8%.

The bio production hub is the Chungju Smart Factory, completed in 2021, which received KGMP certification in August 2023 and a GMP certification for contract bio-manufacturing in November 2024. The company said the site can produce from raw materials to finished products, including plasmid DNA, viral vectors and mRNA.

The core pipeline asset is NG101, a gene therapy for wet age-related macular degeneration co-developed with its partner company, in which Reyon is the largest shareholder and handles joint R&D and global production and supply.

The hemostatic thrombin business is described by the company as a high-margin product with an operating margin above 40%, and reports say a supply contract with one large Japanese pharmaceutical company is in progress. The company website states that the largest shareholder family holds a stake of about 54%.

In bio CDMO, Reyon competes with large contract manufacturers such as Samsung Biologics, and the company highlights its raw-material production capability and the Chungju plant's GMP certifications as differentiators.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩37.6B-₩7.2B−19.2%
2025Q4₩33.9B-₩8.2B−24.1%
2026Q1₩36.1B-₩6.7B−18.5%
2026Q2₩35.8B-₩7B−19.5%
2026Q3₩34B-₩9.2B−27.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩154B₩9.6B₩7.4B6.3%3.0%95.6%
2023₩151.1B₩4B₩3.6B2.7%1.4%101.0%
2024₩148.3B₩79,259,194₩4.2B0.1%1.7%100.0%
2025₩145.9B-₩30.3B-₩29.6B−20.7%−13.5%111.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, annual revenue went from KRW 154 billion in 2022 to KRW 151.1 billion in 2023 (down 1.9%), KRW 148.3 billion in 2024 (down 1.8%) and KRW 145.9 billion in 2025 (down 1.6%), a three-year consecutive decline from 2023 through 2025, with 2022 the largest year in the 2022 to 2025 span.

Operating profit fell from KRW 9.63 billion in 2022 to KRW 4.03 billion in 2023 (down 58.1%) and KRW 79.26 million in 2024 (down 98.0%), and the company swung to an operating loss of KRW 30.3 billion in 2025.

The operating margin declined from 6.3% in 2022 to 2.7% in 2023 and 0.1% in 2024 before reaching -20.7% in 2025. The company attributed the 2025 decline to a partial revenue drop from drug price cuts and higher cost of sales from recognizing depreciation on the Chungju plant.

The SG&A ratio fell from 54.5% in 2021 to 49.7% in 2024 and 47.8% in 2025, but this did not offset the cost burden. Industry reporting put depreciation at KRW 1.808 billion in Q3 2024 and KRW 22.382 billion in Q3 2025.

Net profit attributable to owners fell from KRW 4.15 billion in 2024 (up 15.8% from 2023 at KRW 3.58 billion) to a net loss of KRW 29.6 billion in 2025, which was also the 2025 net loss including non-controlling interests.

Operating cash flow moved from -KRW 1.44 billion in 2024 to KRW 1.46 billion in 2025, a return to positive. Quarterly revenue went from KRW 37.6 billion in Q3 2025 to KRW 36.1 billion in Q1 2026, the peak, then fell in Q2 2026 to KRW 35.8 billion and in Q3 2026 to KRW 34 billion, a two-quarter decline.

The operating loss has been reported in five straight quarters, from KRW 7.2 billion in Q3 2025 to KRW 9.25 billion in Q3 2026, and the four quarters from Q4 2025 to Q3 2026 add up to a combined net loss attributable to owners of KRW 42.5 billion.

Based on a trade press report citing the first-half filing, first-half 2026 revenue was KRW 71.9 billion, down 3.4% year on year, and the operating loss narrowed to KRW 13.6 billion from KRW 14.9 billion.

The debt-to-equity ratio rose from 95.6% in 2022 to 111.1% in 2025, with total liabilities of KRW 244.8 billion and total equity of KRW 220.3 billion at end-2025.

05

Industry analysis

The pharmaceutical sector faces pressure on revenue from drug price cuts, which Reyon itself cited as one reason for its 2025 revenue decline.

In wet age-related macular degeneration, standard therapy averages 9.8 injections a year, and the company positions NG101 as a gene therapy aiming for long-lasting effect from a single dose. Gene therapy manufacturing is complex and costly, so yield and cost control are treated as decisive for competitiveness.

Reyon announced in October 2026 that its AAV production yield rose more than threefold versus the prior process, and said it will apply the technology first to the NG101 production process.

A June 2026 report said Japanese gene therapy developers were expected to visit the Chungju Smart Factory in July, and industry observers read this as partners securing production and supply ahead of global trials and commercialization.

In the macular field, the partner company presented interim mid-dose data for NG101 as an oral presentation at ASRS 2026 in July 2026. In a June 2026 report headline, the company highlighted its push into a hemostatic market it described as about KRW 300 billion in size.

In CDMO, industry commentary holds that utilization would rise and margin recovery could accelerate once CGT raw-material production and bio CDMO orders scale up.

Competitively, Reyon positions itself as a specialty pharmaceutical maker spanning raw materials to finished products, but closing the scale gap with large bio CDMO players such as Samsung Biologics will depend on proving commercial utilization at Chungju.

06

Outlook

The most concrete plan the company has given is to expand products and volume at the Chungju plant from 2026 and raise utilization step by step. At end-Q3 2025 the company omitted the utilization figure because the plant was not yet in commercial operation, so the timing of any utilization disclosure is a checkpoint.

The company has said that orders below the disclosure threshold are coming in steadily. It is preparing to release 12-month-plus follow-up data and mid- and high-dose group data for NG101 in the second half of 2026.

Once NG101 moves into commercialization, the company's stated plan is for Chungju to serve as its GMP production base for global supply.

For thrombin, the company is pursuing overseas entry on the back of a supply arrangement with a large Japanese pharmaceutical company, and it expects related revenue to exceed KRW 10 billion in 2027.

The Japanese MRSA antibiotic raw material has completed local registration and will be supplied under a five-year long-term contract.

On funding, Reyon has decided on a KRW 21 billion CB issue and is pursuing monetization of part of the Chungju site for KRW 100 billion or more, with a Korean brokerage named as lead manager. Next checkpoints are the additional second-half 2026 trial data, Chungju utilization, and whether order disclosures materialize.

07

Valuation

PER
—
PBR
1.0×
ROE
-20.4%
EPS
-₩2,316
BPS
₩9,966
Dividend per share
₩0

Because the last four quarters have all been net losses, earnings-based price multiples cannot be computed. The price-to-book ratio sits below 1x, which means the stock trades at a discount to net assets.

Total equity is KRW 220.3 billion, and industry reporting puts the Chungju investment at KRW 324.6 billion, so whether those assets convert into operating profit is the key variable for asset-based measures. The dividend yield is near zero, which places shareholder payouts below the sector average.

Industry analysts read the stock trading below net assets as the market reflecting Chungju's operating results conservatively. The bear counterpoint is that without higher utilization, the fixed cost burden persists.

The factual anchors for the valuation discussion are Chungju utilization, the operating margin in the annual report, and progress on the CB issue and asset monetization.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Chemical segment stays profitable

The company said the chemical segment's annual operating profit rose from KRW 4.6 billion in 2023 to KRW 5.6 billion in 2024 and KRW 8.3 billion in 2025, and that it stayed profitable in Q1 2026 with KRW 2.7 billion of operating profit, per a May 27, 2026 announcement.

Even while consolidated operating losses continue, this segment is shown to earn at the operating level. The rise in product sales share from 68.6% in 2021 to 76.5% in Q3 2025 is also cited as evidence of core business resilience.

NG101 trial data accumulating

According to the company, the NG101 low-dose group averaged 1.1 injections over 52 weeks, about 89% fewer than the 9.8 annual injections on standard therapy. An October 2026 report also noted an average gain of 7 letters on the eye chart in the high-dose group.

With 12-month-plus follow-up and mid- and high-dose data planned for the second half of 2026, confirmed results would strengthen the commercial production case for Chungju.

High-margin thrombin and overseas supply expansion

The company describes thrombin as a high-margin product with an operating margin above 40%, and reports say supply contracts with a large Japanese pharmaceutical company and its US partner are in progress. The company expects related revenue to exceed KRW 10 billion in 2027.

The Japanese MRSA antibiotic raw material, supplied under a five-year contract, forms another overseas revenue stream.

09

Bear factors

Five straight quarters of operating losses

Operating losses have run for five consecutive quarters from Q3 2025 through Q3 2026, and the Q3 2026 loss of KRW 9.25 billion widened from the prior quarter. The Q3 2026 net loss attributable to owners of KRW 12.1 billion was a wider loss than a year earlier.

Net losses attributable to owners over the four quarters from Q4 2025 to Q3 2026 total KRW 42.5 billion. Revenue has also declined for two consecutive quarters, reaching KRW 34 billion in Q3 2026.

Financial burden and reliance on funding

Debt-to-equity stood at 111.1% at end-2025, with total liabilities of KRW 244.8 billion exceeding total equity of KRW 220.3 billion. Total borrowings at end-first-half 2026 were reported at about KRW 215 billion.

The KRW 21 billion CB carries a 0% coupon and a 3% maturity yield, but the financial burden only eases in practice once the Chungju monetization and CB funding are executed.

Uncertainty over Chungju plant utilization

At end-Q3 2025 the company omitted the Chungju utilization figure because the plant was not yet in commercial operation. Industry reporting says depreciation rose from KRW 1.808 billion in Q3 2024 to KRW 22.382 billion in Q3 2025, weighing on results through fixed costs.

Industry observers see normal operation of the plant, which absorbed KRW 324.6 billion, as the key variable for growth.

10

Risk factors

Funding execution

The KRW 21 billion CB and the monetization of KRW 100 billion or more at Chungju have not yet been executed. The monetized assets are idle facilities and land at the site, so actual proceeds may differ depending on deal terms.

If funding slips against roughly KRW 215 billion in total borrowings, financial flexibility would be constrained.

Trial and commercialization timing

NG101 remains in Phase 1/2a, and its commercialization timing will depend on trial results. Even with a strong low-dose result, the mid- and high-dose and long-term follow-up data must point in the same direction. Any slippage in the trial schedule would also delay the outlook for bio utilization at Chungju.

Cost structure and drug pricing

The company itself cited drug price cuts as a reason for the 2025 revenue decline. If depreciation at Chungju keeps lifting cost of sales while existing product revenue erodes, operating margin recovery stays constrained until utilization rises.

If the thrombin and overseas raw-material supply does not proceed on schedule, the timing of higher-margin revenue growth also slips.

11

What to watch next

  1. Before December 31, 2026 (second-half 2026 disclosure plan)

    Whether 12-month-plus follow-up and mid- and high-dose NG101 data are released. Chungju is the planned production base at commercialization, so follow-up results tie directly to plant utilization.

  2. Around early February 2027

    The 2026 Q4 and full-year provisional earnings release. The 2025 full-year provisional results were disclosed on February 10, 2026. The checkpoints are whether the operating margin recovers from -20.7% and whether the loss streak extends beyond five quarters.

  3. By March 31, 2027 (statutory filing deadline)

    Filing of the 2026 annual report on DART. It will carry the confirmed full-year figures for revenue, operating margin, debt-to-equity and operating cash flow, and the comparison with the 2025 report is the key read-across.

  4. Second half of 2026 (timing not set)

    Whether the monetization of idle facilities and land at Chungju for KRW 100 billion or more proceeds, and whether the KRW 11 billion fourth-tranche and KRW 10 billion fifth-tranche CB funds are drawn. Execution would show up in total borrowings and interest burden.

  5. During 2027

    Whether thrombin-related revenue exceeds KRW 10 billion in 2027 and whether supply to Japan and the US begins. The company expects the 2027 milestone, and an August 2026 report had anticipated initial shipments.

12

Overall view

Reyon's revenue fell from KRW 154 billion in 2022 to KRW 145.9 billion in 2025, a three-year decline, and the company swung to an operating loss of KRW 30.3 billion in 2025.

The company cited drug price cuts and higher cost of sales from Chungju depreciation, and operating losses have run for five straight quarters through Q3 2026.

The company says its chemical segment stayed profitable through Q1 2026, while NG101 low-dose trial results and overseas thrombin supply are presented as growth evidence.

On the other side, debt-to-equity rose to 111.1%, and the KRW 21 billion CB and the KRW 100 billion or more asset monetization are in progress, making funding execution a key variable.

On valuation, earnings-based multiples cannot be computed and the price-to-book ratio sits below 1x, and industry reading is that the market reflects Chungju's results conservatively. The next checkpoints are Chungju utilization, NG101 follow-up data, and the operating margin in the 2026 annual report.

Strengths and weaknesses coexist on roughly equal footing, and this is a information-only summary that does not include a buy or sell view.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. dailypharm.com
  2. thebionews.net
  3. v.daum.net
  4. pharm.edaily.co.kr
  5. m.dailypharm.com
  6. thebionews.net
  7. m.yakup.com
  8. thebionews.net
  9. thebionews.net
  10. dailymedi.com
  11. mt.co.kr
  12. reyonpharm.co.kr
  13. reyonpharm.co.kr
  14. m.news.nate.com
  15. reyonpharm.co.kr
  16. alphasquare.co.kr
  17. paxnet.co.kr
  18. catch.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis